EEDi-5273

Cat. No. M11355

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.

Eedi-5273 is a potent and orally effective EED inhibitor (IC50 = 0.2 nM) that can achieve complete and sustained tumor regression.

Molecular Weight	526.49
Formula	C26H22F4N6O2
CAS Number	2585648-55-9
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related PRC2/EED Products
EED226 EED226 is an effective, selective and orally active Polycomb reactive complex 2 (PRC2) inhibitor. When h3k27me0 peptide is used as substrate, ic50=23.4 nm; With mononucleosome as substrate, ic50=53.5 nm. It is a first in class, effective, orally bioavailable inhibitor of embryonic ectodermal development (EED) with strong anticancer effect.
MAK683 MAK-683 is a potent inhibitor of embryonic ectoderm development protein (EED) and allosteric inhibitor of polycomb repressive complex 2 (PRC2).
A-395 A-395 is A Polycomb inhibitory complex 2 (Polycomb repressive complex 2; PRC2), a protein-protein interaction antagonist, inhibits the trimer PRC2 complex (ezh2-EED -SUZ12) with an IC50 value of 18 nM.
ORIC-944 ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.

Catalog